J B Chemicals & Pharmaceuticals Ltd. News and Updates

Name: Latest research reports of J B Chemicals & Pharmaceuticals Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: J B Chemicals & Pharmaceuticals Ltd.
Rating: 5
Author: Prabhudas Lilladhar

Keep track of all breaking news on J B Chemicals & Pharmaceuticals Ltd. from all sources in a single place.

Load latest

J B Chemicals & Pharmaceuticals Ltd.

12 Aug 2024

1639.20

0.56%

JB Chemicals Q1 Results Review - Domestic Business, CMO To Drive Future Growth: Nirmal Bang

NDTV Profit

The five-year average EV/Ebitda of the company is 21x and the brokerage is valuing it at 23x on the back of strong growth in acquired brands and IPM-beating performance.

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

J B Chemicals & Pharmaceuticals Ltd.

10 Aug 2024

1639.20

0.56%

J B CHEMICALS & PHAR

Buy: J B Chemicals & Pharmaceut...

Target

Prabhudas Lilladhar

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

J B Chemicals & Pharmaceuticals Ltd.

09 Aug 2024

1639.20

0.56%

J B Chemicals & Pharmaceuticals Results Earnings Call for Q1FY25

Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.

audio

J B Chemicals & Pharmaceuticals Ltd.

08 Aug 2024

1639.20

0.56%

JB Chemicals & Pharma Q1 results: Net profit jumps 25% to Rs 177 cr

Business Standard

JB Chemicals & Pharmaceuticals on Thursday said its net profit increased 25 per cent year-on-year to Rs 177 crore in the first quarter ended June 30, 2024. The drug firm had reported a net profit of Rs 142 crore in the April-June period last fiscal. Total income increased to Rs 1,010 crore in the June quarter from Rs 902 crore in the year-ago period, JB Pharma said in a regulatory filing. "Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin," CEO and Wholetime Director Nikhil Chopra stated. Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth, he added. "We expect the international business including CDMO business to pick up in the second half of the financial year. The good start .

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

J B Chemicals & Pharmaceuticals Ltd.

01 Jul 2024

1639.20

0.56%

Kotak Equities initiates coverage on JB Chemicals with a target price of Rs 2,025

Economic Times

Having primarily grown organically until FY2022 and later on aided by benefits from acquired brands, JB has handsomely outperformed the IPM in the past decade by ~600 bps and currently ranks 22 in the IPM, said Alankar Garude, Analyst at Kotak Equities.

J B Chemicals & Pharmaceuticals Ltd. is trading below its 50 day SMA of 1678.7

Stock Of The Day: JB Chemicals Surges After Kotak Initiates 'Buy'

NDTV Profit | 01 Jul 2024

J B Chemicals & Pharmaceuticals Ltd.

30 May 2024

1639.20

0.56%

JB Chemicals looks to double revenue with expansion in the domestic market

Business Today

Analyst at ICICI Securities expecting revenue contributions from India and CMO businesses to rise from 67% to 75%

Number of FII/FPI investors increased from 279 to 294 in Dec 2024 qtr.

J B Chemicals & Pharmaceuticals Ltd.

22 May 2024

1639.20

0.56%

JB Chemicals Q4 Results Review - Domestic Business, CMO To Drive Future Growth: Nirmal Bang

NDTV Profit

We have trimmed down are revenue as well as gross margin expectations, thereby reducing our estimates by 9.4%/4.1% for FY25E/FY26E.

J B Chemicals & Pharmaceuticals Ltd. is trading below its 50 day SMA of 1678.7

J B Chemicals & Pharmaceuticals Ltd.

22 May 2024

1639.20

0.56%

Steady outlook; valuation pricey

Hold: J B Chemicals & Pharmaceut...

Target

ICICI Securities Limited

JB Chemical’s (JB Chem) Q4FY24 EBITDA and profits were below our expectation. Q4 sales benefitted from the distribution agreement for its ophthalmology brands with Novartis, partially offset by the discontinuation of the tender business in South Africa.

J B Chemicals & Pharmaceuticals Ltd.'s price crossed above 30Day SMA today

J B Chemicals & Pharmaceuticals Ltd.

22 May 2024

1639.20

0.56%

BP Equities Q4FY24 Result Update JB Chemicals and Pharmaceuticals Ltd

Results Update: J B Chemicals & Pharmaceut...

BP Wealth

J B Chemicals & Pharmaceuticals Ltd.'s price crossed above 30Day SMA today

J B Chemicals & Pharmaceuticals Ltd.

21 May 2024

1639.20

0.56%

J B Chemicals & Pharmaceuticals Results Earnings Call for Q4FY24

Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.

audio